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Linezolid is a treatment option for methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic
fibrosis (CF) patients. Little is known, however, about its pharmacokinetics in this population. Eight adults
with CF were randomized to receive intravenous (i.v.) and oral linezolid at 600 mg twice daily for 9 doses in
a crossover design with a 9-day washout. Plasma samples were collected after the first and ninth doses of each
phase. Population pharmacokinetic analyses were performed by nonlinear mixed-effects modeling using a
previously described 2-compartment model with time-dependent clearance inhibition. Monte Carlo simulation
was performed to assess the activities of the linezolid dosing regimens against 42 contemporary MRSA isolates
recovered from CF patients. The following pharmacokinetic parameter estimates were observed for the
population: absorption rate constant, 1.91 h1; clearance, 9.54 liters/h; volume of central compartment, 26.8
liters; volume of peripheral compartment, 17.3 liters; and intercompartmental clearance, 104 liters/h. Linezolid
demonstrated nonlinear clearance after 9 doses, which was reduced by a mean of 38.9% (range, 28.8 to 59.9%).
Mean bioavailability was 85% (range, 47 to 131%). At steady state, 600 mg given twice daily produced 93.0%
and 87.2% probabilities of obtaining the target pharmacodynamic exposure against the MRSA isolates for the
i.v. and oral formulations, respectively. Thrice-daily dosing increased the probabilities to 97.0% and 95.6%,
respectively. Linezolid pharmacokinetics in these adults with CF were well described by a 2-compartment
model with time-dependent clearance inhibition. Standard i.v. and oral dosing regimens should be sufficient to
reliably attain pharmacodynamic targets against most MRSA isolates; however, more frequent dosing may be
required for isolates with MICs of >2 g/ml.
The incidence of methicillin-resistant Staphylococcus aureus
(MRSA) in cystic fibrosis (CF) patients has been steadily in-
creasing over the past 15 years. According to the Cystic Fibro-
sis Foundation patient registry annual report, 0.1% of positive
respiratory specimen cultures were due to MRSA in 1995, and
as of the last published report in 2009, this had increased to
23.7% (8). Until recently, it was unknown what influence this
increase in incidence had on clinical outcomes. Pediatric pa-
tients with respiratory specimen cultures persistently positive
for MRSA have significant reductions in lung function (10).
Furthermore, the chronic presence of MRSA-positive cultures
for CF patients of any age is associated with decreased survival
(9). Due to these negative clinical outcomes, clinicians have
become more conscious of the presence of respiratory MRSA
and the need for treatment in these patients.
Although linezolid, an oxazolidinone antibiotic with in vitro
activity against MRSA, is a treatment option for CF patients
with acute exacerbations, little is understood about its phar-
macokinetics in this population. Previous studies have pro-
posed that CF patients with inadequate clinical responses may
require more frequent dosing due to variability in their phar-
macokinetic parameters (3, 22). Neither of these studies, how-
ever, considered the potential for nonlinear elimination of
linezolid, which has been demonstrated in other populations
after multiple doses (2, 19, 20). Additionally, no study has
assessed the bioavailability of linezolid in CF patients, a pop-
ulation that often exhibits malabsorption. The present study
was undertaken to describe the pharmacokinetics of intrave-
nous (i.v.) and oral linezolid in adults with CF and determine
the pharmacodynamic profile of multiple linezolid dosing reg-
imens against contemporary MRSA isolates.
MATERIALS AND METHODS
Study design. This study was a prospective, single-center, crossover pharma-
cokinetic analysis of i.v. and oral linezolid in outpatient adults with CF, con-
ducted at the Clinical Research Center at Hartford Hospital (Hartford, CT). The
protocol was approved by the Hartford Hospital Institutional Review Board
(KUTI002983HE), and all participants provided written informed consent prior
to study screening.
Participants. Inclusion criteria required that each participant be greater than
or equal to 18 years of age with known CF on the basis of a prior elevated sweat
chloride level or an abnormal CF transmembrane regulator genotype. A prestudy
screening consisting of a detailed medical history, physical examination, and
diagnostic testing (including vital signs, blood/urine laboratory testing, and spu-
tum culture) was performed within 28 days prior to study drug administration.
Participants were excluded if they had clinically significant increases or decreases
in baseline lab results, if they had a known linezolid-resistant MRSA infection or
a known Burkholderia cepacia complex infection, or the presence of an ongoing
acute exacerbation of their lung infection. The participants were to abstain from
alcohol-, nicotine-, and caffeine-containing products during both study phases.
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Linezolid dosing and blood sampling. Commercially available prepackaged
preparations of 600 mg i.v. (lot 09D07Z10; expiration date, April 2012) and oral
(lot C091093; expiration date, December 2011) linezolid (Zyvox; Pfizer Inc., New
York, NY) were supplied by Pfizer Inc. and stored according to manufacturer
recommendations. Participants were randomized to initially receive either i.v. or
oral linezolid at 600 mg twice daily for 9 doses. The i.v. formulation of linezolid
was completely infused over 30 min through a peripheral i.v. catheter, and the
oral formulation was swallowed with a glass of water. Food was prohibited for 1 h
prior to and 2 h after each dose. Blood samples were collected from a peripheral
catheter contralateral to the one used for dosing at time zero (prior to dosing),
0.5, 0.75, 1, 1.25, 1.5, 2, 4, 6, 8, and 12 h after the first and ninth doses. After at
least a 9-day washout period, participants returned to the study center and were
crossed over to receive the alternate formulation, and the same dosing and blood
sampling schemes were repeated. Blood samples were centrifuged (1,000  g at
10°C for 10 min) immediately after collection. Separated plasma was stored at
80°C and protected from light until further analysis.
Linezolid concentration determination. Linezolid concentrations in plasma
were assessed using a validated high-performance liquid chromatography
(HPLC) method modified from a previously published assay (5). The standard
curve was extended from 20 g/ml to 30 g/ml, and the extraction was modified
from deproteinization with 200 ml of acetonitrile to deproteinization with 150 ml
of 7.5% trichloroacetic acid with no drying step. The lower limit of detection of
the assay was 0.2 g/ml. The mean interday coefficients of variation for high-
concentration (20 g/ml) and low-concentration (0.5 g/ml) check samples were
4.3% and 2.0%, respectively. The mean intraday coefficients of variation were
3.2% and 2.4%, respectively.
Pharmacokinetic analyses. Population modeling of linezolid plasma concen-
trations was performed by nonlinear mixed-effects modeling (NONMEM, ver-
sion VI; ICON Development Solutions, Manchester, United Kingdom) using a
2-compartment model with time-dependent inhibition (Fig. 1), which has been
well described previously (20). First-order conditional estimation with interac-
tion was used as the estimation method. The following parameters were esti-
mated: absorption rate constant (ka), volume of distribution of the central com-
partment (V2), intercompartmental clearance (Q), volume of distribution of the
peripheral compartment (V3), rate constant for transfer into the inhibition com-
partment (kic), total body clearance, and the maximum fraction of clearance that
cannot be inhibited after infinite doses (RCLF). Model fit was assessed by
changes in the objective function value (OFV); goodness-of-fit plots; visual
predictive checks; and plausibility and precision of estimated parameters. Abso-
lute bioavailability was calculated for each participant by comparing model-
derived profiles between i.v. and oral regimens. Covariate relations of height,
weight, and lean body weight on clearance, V2, V3, ka, bioavailability, Q, and
RCLF were implemented as a proportional change of the population value,
centered on the median of the covariate. The covariate analysis was performed
using the stepwise forward inclusion (statistical significance level of delta OFV,
P  0.05) and backward elimination procedure (P  0.001).
Susceptibility testing. Forty-two MRSA isolates collected from adolescent
patients in 6 states between October 2008 and December 2009 during a separate
CF surveillance study were supplied for linezolid MIC determination. MICs were
determined in triplicate by Etest (lot BJ0773; expiration date, April 2014; AB
bioMérieux, Solna, Sweden) and read at 90% inhibition according to manufac-
turer instructions.
Monte Carlo simulation. A 1,000-patient Monte Carlo simulation was con-
ducted to determine the probability of achieving requisite in vivo exposures for
a simulated CF patient receiving 600 mg twice daily or thrice daily (for both i.v.
and oral regimens) using the pharmacokinetic parameter estimates and variabil-
ity derived from the model. The median lean body weight for the population was
fixed in the covariate model to predict clearance and ka. The total drug area
under the concentration-time curve over 24 h (AUC) was calculated by
NONMEM as the integral of the simulated concentration-time profile. The
probability of target attainment (PTA), which is the likelihood that the regimen
will meet or exceed the predefined pharmacodynamic target at a specific MIC
dilution, was calculated. The pharmacodynamic exposure target was a ratio of
the AUC to the MIC (AUC/MIC) of 83 (1, 18, 21). PTAs for each regimen
were used to calculate the cumulative fraction of response (CFR) against the
MRSA population. CFR is the probability that the dosing regimen will attain its
pharmacodynamic index against the entire population of organisms.
RESULTS
Eight participants with mild to moderate lung disease were
enrolled in the study; however, 1 male was withdrawn after
completing only the i.v. formulation phase due to the devel-
opment of a maculopapular rash. His i.v. plasma concentra-
tions were included in the pharmacokinetic model. Participant
characteristics are provided in Table 1. Overall, linezolid was
well tolerated, with only mild and transient adverse events.
Diarrhea (n  3), headache (n  2), and nausea (n  2) were
the most commonly reported adverse events, and no thrombo-
cytopenia was observed in any of the participants.
FIG. 1. Population pharmacokinetic model for linezolid plasma
concentrations in cystic fibrosis patients. Clearance is inhibited on the
basis of the concentration in a theoretical inhibition compartment. KA,
absorption rate constant; ALAG, absorption lag time; CL, clearance;
KIC, rate constant into inhibition compartment (inhib. comp.); IC50,
inhibition compartment concentration yielding 50% of maximum
clearance inhibition; periph., peripheral.
TABLE 1. Characteristics of the 8 cystic fibrosis participants at baselinea
Subject no. Sex CF genotype Age (yr) ABW (kg) LBWb (kg) BMI (kg/m2) Ht (m) FVC (%c) FEV1 (%c)
1 Male 35 63.4 54.0 19.4 1.81 81 66
2 Male F508/F508 24 93.6 69.5 27.9 1.83 74 60
3 Male F508/— 47 69.5 54.0 25.2 1.66 36 32
4 Male F508/F508 25 57.7 50.3 17.8 1.80 70 46
5 Male F508/G551D 29 79.1 59.3 27.3 1.70
6 Male G524Z/R1303K 24 52.3 44.4 19.7 1.63 41 23
7 Female 24 55.5 39.7 24.0 1.52
8 Male F508/F508 23 65.5 54.9 20.4 1.79 70 44
Mean 28 67.1 53.3 22.7 1.72 62.0 45.2
SD 8 13.7 9.1 3.9 0.11 18.7 16.3
a ABW, actual body weight; LBW, lean body weight; BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume over 1 s.
b Calculated by the James equation (16a).
c Percent predicted.
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The mean i.v. and oral linezolid plasma concentrations over
12 h after the first and last (i.e., steady-state) doses are pre-
sented in Fig. 2. Typical values for the population pharmaco-
kinetic parameter estimates are listed in Table 2. The final
model’s goodness-of-fit plot for observed versus predicted con-
centration and weighted residuals versus time are presented in
Fig. 3A and B. After multiple doses, linezolid displayed non-
linear clearance, where the mean individual initial clearance
was 9.7 liters/h (range, 3.6 to 14.2 liters/h) and the mean clear-
ance after the ninth dose was 6.1 liters/h (range, 1.8 to 9.8
liters/h). This was a reduction in clearance by 38.9% (range,
28.8% to 59.9%), with a maximum potential model estimated
reduction of 67.9%. Increases and decreases in median lean
body weight were associated with proportional changes in both
ka (4.74% per kilogram) and clearance (3.35% per kilogram).
Mean bioavailability was 85.1% and ranged from 47% to
137%.
The linezolid MIC range for the 42 MRSA isolates was 0.5
to 256 g/ml, with only a single isolate (2.5%) found to be
resistant to linezolid. The MIC50 and MIC90 were 1.0 and 1.5
g/ml, respectively. The probabilities of achieving target AUC/
MIC exposures of 83 at steady state for simulated linezolid
regimens are shown in Fig. 4. (PTA curves for the first 24 h of
dosing are not shown.) Due to higher clearances after initial
doses, the CFRs for the first day of i.v. or oral dosing were
73.5% and 59.6%, respectively, for the twice-daily regimens.
Increasing the dose to three times a day provided CFRs of
90.9% and 82.2% for the i.v. and oral formulations, respec-
tively, on the first day of therapy. After multiple doses, the
CFRs for 600 mg i.v. and orally twice daily increased to 93.0%
and 87.2%, respectively, while the CFRs for 600 mg i.v. and
orally three times daily increased to 97.0% and 95.6%, respec-
tively.
DISCUSSION
As the incidence of MRSA exacerbations in CF patients
increases, the need for alternative antibiotic options to that of
i.v. vancomycin has become apparent. Case reports have doc-
umented successful treatment of MRSA infections with lin-
ezolid in patients with CF (12, 25, 26). It has also been evident
that prolonged treatment with low doses of linezolid results in
the development of resistance (13, 15). Thus, dosing regimen
selection is critical in achieving a successful response while
minimizing the development of resistance and adverse events.
Herein, we describe the population pharmacokinetics of lin-
ezolid in eight adult CF participants using a previously de-
scribed 2-compartment model with a theoretical inhibition
compartment (20). This model accurately described linezolid
pharmacokinetics in these participants and generally resulted
in mean parameter estimates similar to those for healthy vol-
unteers and septic shock patients, albeit with lower absolute
TABLE 2. Pharmacokinetic parameter estimates for the final model




Clearance liters/h 9.54 15.4
V2 liters 26.8 8.3
V3 liters 17.3 42.3
Q liters/h 104 18.4
ka liters/h 1.91 12.9
Bioavailability % 85.1 10.0
Kic liter/h 0.0005
RCLF % 32.1 36.1
IC50 mg/liter 0.38 32.3
Covariate influence
LBW on ka %/kg 4.74 5.76
LBW on clearance %/kg 3.35 35.5
Between-patient variability
Clearance % CV 36.3 46.7
V3 % CV 85.8 70.4
RCLF % CV 58.3 100
Bioavailability % CV 23.0 47.6
Residual variability,
proportional error
% CV 22.4 18.6
a RSE, relative standard error; IC50, inhibition compartment concentration
yielding 50% of maximum clearance inhibition; LBW, lean body weight; CV,
coefficient of variation.
FIG. 2. Mean and standard deviation intravenous (A) and oral
(B) linezolid plasma concentrations over 12 h for cystic fibrosis par-
ticipants after the first dose and at steady state.
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bioavailability (20). Importantly, nonlinear clearance was evi-
dent in all participants, thereby increasing linezolid exposure
after multiple dosing and suggesting that standard linezolid
dosing regimens (i.e., 600 mg i.v. or oral twice daily) should be
sufficient to achieve critical pharmacodynamic targets for most
MRSA isolates.
Few studies have evaluated linezolid pharmacokinetics in
CF patients (3, 22, 23), and all of these studies determined the
pharmacokinetics of linezolid by noncompartmental methods,
making direct comparisons with our pharmacokinetic param-
eters inappropriate. The earliest study described linezolid dis-
position after a single i.v. dose of 600 mg in 12 adult CF
patients admitted to the hospital for an acute exacerbation (3).
By comparing dose-normalized AUCs, similar results between
their study and ours (0.187 g  h/ml mg and versus 0.212
g  h/ml or mg, respectively) were observed from a single
600-mg i.v. dose. A second study in 10 CF adults receiving
multiple oral doses of linezolid observed lower concentrations
at 2 and 4 h after dosing compared with those in healthy
volunteers; however, this study had a sparse sampling strategy,
did not collect serum after the first dose, and did not report
pharmacokinetic parameter estimates (23). Their mean 2-hour
serum concentration after multiple dosing was in concordance
with our 2-hour steady-state oral plasma concentration (13.5
g/ml versus 12.7 g/ml, respectively); however, their reported
mean 4- and 12-hour concentrations (8.1 g/ml and 2.3
g/ml, respectively) were substantially lower than our con-
centrations (11.9 g/ml versus 5.5 g/ml, respectively) for
these time points. This may be partially explained by differ-
ences in the number of doses prior to sampling; although
steady state would typically be reached by either 6 or 9 doses,
clearance inhibition is time dependent; thus, our participants
may have had higher concentrations due to more apparent
clearance inhibition. The final study (22) also had a sparse
sampling strategy (peak and trough only), used noncompart-
mental methods, and enrolled 10 children (age range, 4 to 20
years), with only a single patient being over the age of 16 years,
so it is difficult to make comparisons with our results.
It is well recognized that CF patients can portray pharma-
cokinetic profiles for antibiotics different from those of non-CF
patients (17). Most notably, CF patients tend to have a more
rapid clearance and a greater volume of distribution for anti-
biotics eliminated via glomerular filtration, tubular secretion,
as well as nonrenal metabolism pathways (6, 7, 16, 27). In
non-CF populations, linezolid concentration data are best de-
scribed by nonlinear elimination models (2, 19, 28). The pre-
viously well-described population pharmacokinetic model ap-
plied in this study best predicted parameter estimates and
minimized model misspecifications (20). We also undertook
model comparisons with other nonlinear approaches and
found this model to be the most accurate for describing lin-
ezolid concentrations in these CF patients (24). Our final
model estimates for clearance and volume of distribution were
very similar to those reported for septic shock patients and
FIG. 3. Goodness-of-fit plot of the final model. (A) Dashed line,
observed versus model-predicted linezolid concentrations (r2 
0.66, y  1.08x  0.665); solid line, line of unity; (B) weighted
residuals.
FIG. 4. Probability of target attainment to achieve an AUC/MIC of
83 for two dosing regimens of intravenous and oral linezolid at
steady state. BID, twice a day; TID, three times a day.
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healthy volunteers (20). Notable differences included a more
rapid Q in the CF patients (104 liters/h versus 75 liters/h) and
a lower RCLF (0.321 versus 0.764). With respect to the max-
imal fraction of linezolid clearance that could not be inhibited,
lower estimates suggest that linezolid clearance may be re-
duced to a greater degree in CF patients than other patient
populations.
Additionally, oral bioavailability in our CF population was
found to be approximately 85.1% and was quite variable
(range, 47% to 137%). This observation is substantially differ-
ent from those in studies in non-CF subjects, which have re-
ported linezolid bioavailability of nearly 100% (2, 29). Lin-
ezolid is a moderately lipophilic molecule (4), and pancreatic
enzyme deficiency, which is common in CF patients, can im-
pact the absorption of lipophilic medications (14). It was also
not surprising, then, to observe a positive relationship between
lean body weight and ka (Table 2), suggesting a link between
nutritional status and the rate of antibiotic absorption (i.e.,
those who are malnourished might need higher oral dosages to
obtain similar concentrations). All eight patients received ex-
ogenous oral supplementation of pancreatic enzymes, but at
various doses.
Perceived pharmacokinetic differences in CF patients, com-
bined with a propensity for infection caused by multidrug-
resistant bacteria, often result in the need to administer higher
antibiotic doses to the CF population. Indeed, the previous
pharmacokinetic assessment in adults attempted to elucidate
achievable exposure by dividing the mean AUC by the suscep-
tibility breakpoint (i.e., 4 g/ml), resulting in exceedingly low
AUC/MIC values and a conclusion that linezolid dosing should
be increased in this population (3). However, the MIC50 and
MIC90 observed in our collection of 42 CF isolates were 1.0
and 1.5 g/ml, respectively, which are similar to MIC values
from the most recent linezolid national surveillance program
(LEADER program, 2008) (11). Using the pharmacokinetic
model derived from these 8 participants, we aimed at simulat-
ing AUC/MIC exposures for 1,000 CF patients after the first
24 h and at steady state. Although exposures over the first 24 h
were low for twice-daily dosing, the CFRs at steady state were
93.0% and 87.2% for i.v. and oral doses, respectively. The
likelihood of achieving an AUC/MIC ratio of 83 declines
rapidly once MICs are 2 g/ml or greater (Fig. 4). Empirically
increasing linezolid dosing may put a patient at unnecessary
risk for drug-induced toxicity; therefore, testing the linezolid
MIC prior to selection of a dosing regimen would be of value
in this population. Lastly, this pharmacodynamic target comes
from animal infection models of MRSA and non-CF patient
studies (1, 18, 21). The pharmacodynamic target required for a
successful response in CF patients is unknown.
Linezolid pharmacokinetics in these 8 CF adults were well
described by a 2-compartment model with time-dependent
clearance inhibition. Although interpatient variability was ap-
parent and absolute bioavailability was 85%, standard i.v. and
oral dosing regimens should be sufficient to reliably attain
pharmacodynamic targets against most MRSA isolates. Higher
or more frequent dosing, however, may be required for isolates
with MICs of 2 g/ml. The pharmacokinetics and safety of
higher or more frequent linezolid dosing require further study
in adult patients with CF.
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